Koch Disruptive Technologies, Longliv Ventures, and OurCrowd participated in the round, bringing the firm's total funding to date to more than $124 million.
Pathnova, will further develop and commercialize Todos' tests in Singapore, while Todos will assist Pathnova to commercialize its nasopharyngeal cancer tests.
The agreement is Oncocyte's second distribution deal this year following an agreement with Core Diagnostics to sell the test in Africa and the Middle East.
Todos said that it aims to develop an at-home 3C protease-based kit that uses a cell-phone camera and software for data analysis to test for the coronavirus.
The firm expects to launch a 510(k)-cleared version of its Bladder EpiCheck recurrence assay early next year followed by an RUO early-stage lung cancer assay.
The company is completing a study of its digital microscopy system which uses a computational approach that it said enables high-speed, high-resolution scanning.
